Review on Role of AI in Pharmaceutical Research and Development

Abstract

Artificial intelligence (AI) and machine learning (ML) are expected to have a transformative impact on pharmaceutical research and development (R&D) over the last decade. To choose the study such as "disease diagnosis." In this article, the use of AI in medication discovery, individualized treatment, digital therapy, disease detection, and epidemic or pandemic forecasting was thoroughly examined. Deep learning and neural networks are the most often utilized AI technologies; Bayesian nonparametric models have the potential to be employed in clinical trial design; and natural language processing and wearable devices are used in patient identification and monitoring. In order to anticipate the outbreak of COVID-19, Zika, Ebola, TB, and seasonal influenza, deep learning and neural networks were used. Rapid and economical pharmaceutical and healthcare research, as well as better public services, could be witnessed by the scientific community as AI technologies develop. Artificial intelligence (AI) has emerged as a potent tool for harnessing human knowledge and delivering rapid answers to complicated problems. Remarkable advances in AI technology and machine learning offer a breakthrough possibility for drug development, formulation, and pharmaceutical dosage form testing.

Keywords

Introduction

The demand for a skilled workforce in the healthcare industry is constant, necessitating the ongoing supply of training to healthcare staff to supplement their involvement in normal responsibilities. Identifying skill gaps in the workplace is a critical task for the pharmaceutical sector. It is critical to effectively address the identified deficiencies with suitable corrective procedures, while simultaneously realizing that delivering enough training can be difficult. According to a report prepared by specific agencies, around 41% of supply chain interruptions occurred in June 2022.^1,2 The research also states that supply chain disruption has emerged as the second-most difficult barrier to tackle. Massive amounts of biomedical data are currently being collected following a lengthy period of data collection, in conjunction with the advent of high-throughput. RNA-sequencing technologies Biomedical data, which is highly heterogeneous and complex, is derived from a variety of sources, including omics data from various platforms, experimental data from biological or chemical laboratories, data generated by pharmaceutical companies, publicly disclosed textual information, and manually collected data from publicly available databases. AI may be used to identify potential patterns in massive volumes of biomedical data, creating new opportunities and problems for the pharmaceutical sciences and businesses. ^3,4 In the 14th round of the Critical Assessment of Protein Structure Prediction (CASP14) competition, the AlphaFold2 system outperformed others by utilizing AI. Artificial intelligence (AI) is rapidly changing the face of pharmaceutical research and development (R&D), playing an increasingly important role in speeding up drug discovery, streamlining clinical trials, and improving personalized medicine. AI allows researchers to analyse large datasets, identify hidden patterns, and anticipate molecular interactions with unprecedented accuracy by utilizing machine learning algorithms and advanced data analytics. This capability not only speeds up the identification of prospective drug candidates, but it also saves time and money compared to traditional R&D processes. AI has the ability to repurpose drugs, find biomarkers, and optimize treatment regimens, hence advancing precision medicine and improving patient outcomes. As AI evolves, its incorporation into the pharmaceutical business promises to alter the way we approach medication development, eventually reshaping the future.^5,6

Basic Concepts

AI is transforming pharmaceutical R&D by speeding up the drug discovery process, enhancing clinical trials, and enabling personalized treatment. Machine learning and data analytics enable researchers to evaluate large volumes of biological and chemical data, discover prospective medication candidates, and anticipate how they will interact with the body. AI models can help optimize medicine formulations, forecast adverse effects, and find illness biomarkers, resulting in more targeted and effective treatments. In clinical trials, AI can help with patient recruiting, outcome monitoring, and trial success rate prediction. Finally, AI's role in pharmaceutical R&D not only lowers costs and development time, but it also improves the precision and effectiveness of medicines, allowing new and improved pharmaceuticals to reach the market faster.^7,8

Beginning of Ai In Pharmaceutical Research and Development

The use of AI in pharmaceutical research and development (R&D) dates back to the early 2000s, when the pharmaceutical industry began to adopt computational methodologies to improve drug discovery. Initially, AI was utilized for basic data analysis and pattern recognition, allowing researchers to process massive volumes of chemical, biological, and clinical data more effectively. Early applications included the use of AI algorithms for molecular modelling, virtual drug screening, and chemical property prediction.
As machine learning and neural networks evolved, AI's function grew to include increasingly complicated tasks including forecasting drug efficacy, refining clinical trial designs, and detecting potential side effects.^9,10

As AI technology advanced, particularly with the introduction of machine learning (ML) and deep learning (DL), its applications in pharmaceutical research and development got more complex. Machine learning algorithms were first employed for predictive modelling, allowing researchers to predict how different medications will react in the human body, including their efficacy and probable side effects. These predictive capabilities enabled more targeted medication development and the early identification of molecules with the highest chances of success in clinical trials. AI's contribution in drug candidate optimization was also a significant step toward its inclusion into pharmaceutical research and development.^11,12 AI programs could examine enormous datasets to establish a drug's optimal molecular composition, enhancing efficacy while avoiding toxicity. This approach, known as structure-activity relationship (SAR) modelling, assisted researchers in developing more effective and safe medications. AI also helped to identify disease biomarkers, which was vital in the creation of tailored therapy. Researchers could use AI to examine genomic, proteomic, and clinical data to identify unique genetic or molecular indicators that could determine the best therapy option for individual patients. By the mid-2010s, AI's role in pharmaceutical R&D has grown to clinical trials. AI began to help with patient recruitment by identifying individuals who fit specified criteria, so accelerating the recruitment process and ensuring more targeted participant selection. AI models also assisted in optimizing clinical trial designs by predicting the optimum trial protocols and evaluating parameters such as dose, timing, and patient demographics to increase the likelihood of success.^13,14 Additionally, AI-powered platforms were employed to monitor patient data in real-time during trials, allowing for faster detection of adverse events and increasing trial efficiency. Today, artificial intelligence is an essential component of pharmaceutical research and development. Its ability to evaluate large datasets, forecast therapeutic efficacy and safety, and optimize clinical trials has transformed drug development. AI not only speeds the rate of discovery, but it also lowers costs, increases prediction accuracy, and facilitates the development of individualized therapeutics tailored to specific patients' needs. The introduction of AI in pharmaceutical R&D signals the beginning of a disruptive era, and as technology advances, its impact on the industry will only grow, influencing the future of healthcare.^15,16

AI in Drug Discovery

Artificial intelligence (AI) has had a significant impact on the drug discovery process, which has traditionally been long, complex, and expensive. Researchers have been able to simplify several stages of drug discovery by leveraging machine learning (ML), deep learning (DL), and data analytics, from target identification to lead optimization. The following are key areas where AI plays an important role in drug discovery.^17,18

1. Identifying and Validating Drug Targets Problem: Finding the appropriate biological target (protein or gene) for a disease is challenging. Incorrect targeting can result in failure medications or unexpected side effects. AI Solution: To identify interesting therapeutic targets, machine learning (ML) algorithms evaluate massive volumes of biological data, including gene expression, protein interaction networks, and clinical data. AI can also forecast how a given target will react to a medicine, allowing for more precise validation.
2. Preclinical and Clinical studies Problem: Clinical studies are costly, involve large participant groups, and have high failure rates due to factors such as incorrect patient selection or dosing. AI Solution: AI models can improve trial design by identifying the most likely patient populations, dosage techniques, and biomarkers for success. Furthermore, AI can assist in monitoring patient data during clinical trials in order to detect any harmful effects early on, hence improving patient safety and speeding up decision-making. AI can also help detect clinical trial patterns that may indicate improved outcomes.
3. Biomarker Discovery: Identifying accurate biomarkers is crucial for establishing diagnostic tests and evaluating therapy effectiveness. AI Solution: AI can evaluate clinical, genomic, and proteomic data to identify new biomarkers for illness diagnosis, prognosis, and therapy efficacy. Machine learning algorithms can detect complicated patterns in data that human researchers find difficult to spot.
4. Data Integration and Interpretation: The pharmaceutical sector generates huge amounts of data from genomics, proteomics, and clinical trials, making data integration and interpretation a considerable problem. AI Solution: AI and machine learning techniques may analyse and integrate data from a variety of sources (including genomic, proteomic, and clinical data) to create a comprehensive picture of disease and treatment response. AI models can find hidden correlations inside big datasets that human researchers may miss, enhancing our understanding of disease causes and speeding up medication discovery.
5. Personalized Medicine: Personalized medicine addresses the issue of one-size-fits-all drug development, as individual responses to drugs vary based on genetics.
   AI Solution: AI can evaluate genetic data and provide individualized treatment plans. AI allows for better focused therapeutics by understanding how distinct genetic variations affect medication metabolism or efficacy, boosting outcomes while lowering side effects.
6. Predicting toxicity and side effects: Problem: Drug candidates frequently fail in late-stage clinical trials due to unforeseen toxicity or side effects, resulting in delays and significant expenses. Artificial intelligence models can anticipate toxicity earlier in the medication development process by assessing known data on chemical structures and biological consequences. Machine learning algorithms trained on large chemical databases can predict if a substance will cause toxicity, assisting scientists in identifying potentially dangerous chemicals before they enter clinical trials.^19,20

Pharmacokinetics and Pharmacodynamics (Pk/Pd) Modeling

Pharmacokinetics (PK) and Pharmacodynamics (PD) are two important aspects of drug development that define how a drug interacts in the body and exerts its effects. PK/PD modelling is a mathematical and computational technique to understanding and forecasting these phenomena, which helps guide drug development, optimization, and clinical application.

• Understanding Pharmacokinetics (PK):-

Pharmacokinetics discusses how medications travel through the body over time, with a focus on ADME (Absorption, Distribution, Metabolism, and Excretion). The goal of PK modelling is to predict the drug concentration in the body at any given moment as well as how the body processes the medication.

Key Components of PK: Absorption is the process by which a substance enters the bloodstream after being administered (e.g., orally or intravenously). The spread of a medication through the bloodstream to different tissues and organs in the body. Metabolism is the chemical transformation of a drug by enzymes, typically in the liver, that can activate or deactivate it.
Excretion is the removal of a medication from the body, primarily through the kidneys (urine) or bile (faces).

• PK Parameters: - Cmax: The highest concentration of the medication in the bloodstream.
  Tmax: The time required to reach Cmax.
  Half-life (t1/2): The time it takes for the medication concentration to decrease by half.

Area Under the Curve (AUC): is a measure of total drug exposure over time.
Clearance (Cl): is the amount of plasma from which the drug is eliminated per unit time, demonstrating how quickly the body eliminates the medication.

• Types of PK models: Compartmental Models: These models divide the body into "compartments" (e.g., central and peripheral) and assume that drug concentrations are uniform within each compartment. Rate constants govern how quickly objects travel between compartments.
  The one-compartment model assumes that the drug distributes equally throughout the body shortly after injection.
  Multi-Compartment Models: Used for more complex drug behaviours in which drug delivery occurs in stages rather than immediately.
  Non-Compartmental Models (NCA): These models are based on empirical data and do not assume distinct compartments; they are commonly employed for simple PK investigations.

1.6 Understanding Pharmacodynamics (PD): Pharmacodynamics refers to the biological effects of a medicine on the body, specifically how the drug interacts with its target (e.g., receptors, enzymes) to create therapeutic results. PD modelling connects drug concentration (from PK) to the subsequent effects, which aids in determining the dose-effect relationship.

• Key Components of PD: -
  Drugs work by binding to certain receptors or enzymes. PD modelling investigates how binding affinity and drug concentration relate to the anticipated treatment outcomes.
  Efficacy: A drug's greatest effect, which is generally related to its binding potency or concentration at the site of action.
  Potency is the drug concentration required to achieve 50% of its maximum effect (often represented as EC50 or IC50 for inhibition).
  The therapeutic window is the concentration range in which the medicine is effective without producing toxicity.^21,22

Applications of PK/PD Modelling in Drug Development: -

1. Optimizing Dosage Regimens: PK/PD models assist in determining the ideal dose, dosing timing, and method of administration while maintaining efficacy and safety. A model, for example, can determine the optimal dose interval for maintaining therapeutic medication levels while staying below the toxicity threshold.
2. Predicting Drug Interactions: PK/PD models can predict how different medications will interact, such as one drug influencing another's absorption, metabolism, or excretion, which is critical for polypharmacy.
3. Individualized Medicine (Precision doses): By utilizing patient-specific data (e.g., genetics, comorbidities), PK/PD models can adjust drug doses to individual patients, optimizing efficacy while minimizing side effects.
4. Early Prediction of Drug Safety and Efficacy: PK/PD modelling can assist forecast how potential drug candidates will behave in humans, lowering the likelihood of costly late-stage failures.
5. Bioequivalence Studies: PK/PD models are frequently used to compare the pharmacokinetics and pharmacodynamics of a generic medicine to a brand-name drug to establish therapeutic equivalented.^23,24

AI in Preclinical Research

Preclinical research is critical in determining the safety, effectiveness, and pharmacological features of potential drug candidates. AI can speed up this process by optimizing drug discovery, enhancing animal model selection, and discovering biomarkers for illness and treatment responses.²⁵

Applications of AI in Preclinical Research:

Drug Screening and Hit Identification: has traditionally tested hundreds of chemicals for biological activity. AI models, particularly deep learning algorithms, can better assess the findings of these screens by identifying patterns and forecasting which chemicals are most likely to attach to targets or show desirable behaviour.

Virtual Screening: AI systems use quantum mechanics, molecular docking, and protein-ligand interaction models to predict compounds' binding affinity to therapeutic targets. This helps to choose lead candidates for further in vitro and in vivo testing, lowering the requirement for large compound libraries and experimental expenses.

Finding and Verifying the Target: To find possible therapeutic targets, machine learning can examine enormous volumes of proteomic, transcriptomic, and genomic data. AI can also forecast how certain protein changes or genetic abnormalities may result in illnesses, which makes it possible to create tailored treatments. In order to determine whether altering these targets might be beneficial in treating particular illnesses, AI can also be used to validate possible drug targets by examining historical data, such as clinical trial results, genetic databases, and scientific literature.

Modelling Disease: AI-driven Disease Models: Predictive models of the course of diseases can be produced by machine learning models that can evaluate enormous volumes of patient data. These models can expedite the process of finding prospective therapeutic candidates by simulating how a medicine might intervene in disease systems.

Patient stratification: Based on a patient's genetic composition, comorbidities, and other characteristics, AI can assist in identifying subgroups of patients who are most likely to react to a certain treatment. Selecting preclinical animal models that most closely resemble human disease may be aided by this.^26,27

AI in Drug Pricing and Market Access

One of the most important facets of the pharmaceutical sector is drug pricing, which has a direct bearing on earnings, accessibility to medications, and public opinion. A number of factors must be taken into account when determining a drug's appropriate price, such as the cost of production, the results of clinical trials, market demand, rival prices, and payer reimbursement schemes. Pharmaceutical businesses are using AI-driven solutions to assist them in making evidence-based, data-driven pricing decisions.

Applications of AI in Drug Pricing:

• Price Optimization:
  • AI models can analyse a vast amount of pricing data, including historical drug pricing, competitor prices, demand fluctuations, market trends, and socioeconomic factors. Machine learning algorithms identify patterns and recommend optimal prices for drugs based on these insights, ensuring that pharmaceutical companies set competitive prices without compromising profit margins.
  • Dynamic Pricing Models: AI can be used to implement dynamic pricing strategies, where the price of a drug adjusts over time based on factors like market competition, real-world evidence (RWE), changes in health outcomes, and payer negotiations.
• Predictive Pricing Models:
  • AI tools can predict the future prices of drugs based on a variety of factors such as regulatory decisions, upcoming patent expirations, drug supply chains, and competitor activities. This allows pharmaceutical companies to anticipate changes and optimize their pricing strategy.
  • Elasticity Modelling: AI can predict how sensitive different market segments are to changes in drug prices (price elasticity). This helps determine the potential impact of pricing changes on sales volume, enabling better-informed decisions.
• Incorporating Market and Economic Factors:
  • AI can consider factors beyond the drug itself, such as healthcare system dynamics, cost-effectiveness analysis (CEA), and budget impact models (BIM). AI systems can incorporate healthcare expenditures, potential cost savings, and long-term economic benefits to determine a drug's value proposition.
  • Value-Based Pricing: AI can support value-based pricing by analyzing real-world evidence (RWE) and clinical outcomes to assess the added value of a drug over existing therapies. This allows for more precise pricing based on a drug's actual benefit to patients and healthcare systems.
• Global Pricing Strategies:
  • AI can help pharmaceutical companies determine global pricing strategies by analyzing price sensitivities in different regions. For example, AI can help identify optimal prices for developed and emerging markets based on factors like GDP per capita, healthcare spending, and local reimbursement policies.
• Market Access and Reimbursement Prediction:
  • Payer Modelling: AI systems can predict payer behaviour by analyzing historical data, payer negotiations, formulary inclusion trends, and reimbursement patterns. This helps companies anticipate reimbursement levels and optimize pricing to align with payer expectations.
  • Market Access Simulation: By modelling payer responses and potential market uptake, AI can simulate various pricing scenarios and their effects on reimbursement and sales. This aids in preparing for market access discussions and pricing negotiations with payers.^28,29,30

CONCLUSION

During past few years, a considerable amount of increasing interest towards the uses of AI technology has been identified for analyzing as well as interpreting some important fields of pharmacy like drug discovery, dosage form designing, polypharmacology, hospital pharmacy, etc., as the AI technological approaches believe like human beings imagining knowledge, cracking problems and decision making. The uses of automated workflows and databases for the effective analyses employing AI approaches have been proved useful. As a result of the uses of AI approaches, the designing of the new hypotheses, strategies, prediction and analyses of various associated factors can easily be done with the facility of less time consumption and inexpensiveness.

REFERENCES

1. Mak KK and Pichika MR: Artificial intelligence in drug development: Present Status and future prospects. Drug Discov Today 2019; 24(3): 773-80.
2. Hassanzadeh P, Atyabi F and Dinarvand R: The significance of artificial intelligence in drug delivery system design. Adv Drug Deliv Rev 2019; 151: 169-90.
3. Russel S, Dewey D and Tegmark M: Research priorities for robust and beneficial Artificial intelligence. AI Mag 2015; 36(4): 105-14.
4. Duch W, Setiono R and Zurada JM: Computational intelligence methods for ruleBased data understanding. Proc IEEE 2004; 92(5):771-805 Future. Stroke Vasc Neurol 2017; 2(4): 230- 43.
5. Gobburu JV and Chen EP: Artificial neural networks as a novel approach to Integrated pharmacokinetic pharmaco dynamic analysis. J Pharm Sci 1996; 85(5): 505-10
6. Sakiyama Y: The use of machine learning and nonlinear statistical tools for ADME prediction. Expert Opin Drug Metab Toxicol 2009; 5(2): 149-69
7. Vyas M, Thakur S and Riyaz B: Asian J Pharmaceutics, the birth of AI 2018; 12(02): 72-76.
8. Hargrove MB, Nelson DL and Cooper CL: Generating eustress by challenging employees: Helping people savor their work. Organizational Dynamics 2013; 42: 61-69.
9. Mak KK and Pichika MR: Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today 2019; 24(3): 773-780.
10. Kawal F: A Tour to the World of Artificial Intelligence. Cybernomics 2020; 2(5): 33-35
11. Okafo G: Adapting drug discovery to artificial intelligence. Drug Target Rev 2018; 50-52.
12. Lopes V and Alexandre LA: An overview of blockchain integration with robotics and artificial intelligence. arXiv preprint arXiv:1810.00329, 2018.
13. Mulholland M: A comparison of classification in Artificial intelligence, induction versus a self-organizing Neural

networks Chemometrics and Intelligent Laboratory Systems 1995; 30(1): 117-128.

14. hakya, S., Analysis of artificial intelligence- based image Classification techniques. Journal of Innovative Image Processing (JIIP) 2020; 2(01): 44-54.
15. Manikiran SS and Prasanthi NL: Artificial Intelligence: Milestones and Role in Pharma and Healthcare Sector. Pharma Times 2019; 51(1): 10-1. 16.
16. Cherkasov A, Hilpert K, Jenssen H, Fjell CD, Waldbrook M and Mullaly SC: Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem Biol 2009; 4(1): 65-74.
17. Hintze A: 2016 Understanding the Four Types of AI, from Reactive Robots to Self-Aware Beings.
18. Ravi Kiran T, Naga, Kumar Suresh, Lakshmi GVN and Naseema S: Artificial Intelligence in Pharmacy. Der Pharm Lett 2021; 136-14.
19. Cherkasov A, Hilpert K and Jenssen H: Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic resistant superbugs. ACS Chem Biol 2009; 4(1): 65-74.
20. Klopman A: Artificial intelligence approach to structure Activity studies. Computer automated structure Evaluation
21. of biological activity of organic molecules. J Am Chem Soc 1984; 106: 7315-21.
22. Agatonovic- Kustrin S and Beresford R: Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. J Pharm Biomed

Anal 2000; 22(5): 717-27.

23. Melanie M: An introduction to genetic algorithms.” A bradford book the MIT press Cambridg, Massachusetts. London, England, 1999, Fifth printing.
24. Hayes C., Gedeon T., Hyperbolicity of the fixed-point set for the simple genetic Algorithm. Theorical Computer Science

2010; 411: 24-29.

25. Fazal MI, Patel ME and Tye J: Eur J Radiol, Research and Development of AI 2018; 105: 246-250. Kamal H, Lopez V and Sheth SA: Front Neurol, Drud Develpoment of AI 2018.
26. Mateos-Pérez JM, Dadar M and Lacalle-Aurioles M: Neuroimage Clin, Chemometrics and Intelligent Laboratory Systems 2018; 20: 506-522.
27. Feng R, Badgeley M and Mocco J: J Neurointerv Surg, Journal of Innovative Image Processing (JIIP) 2018; 10(4): 358-362.
28. Melanie M: An introduction to genetic algorithms.” A bradford book the MIT press Cambridg, Massachusetts. London, England.
29. Shampo MA and Kyle RA: J. Craig Venter--The Human Genome Project. Mayo Clinic proceedings 2011; 86(4): e26-e27.
30. Zaharchuk G, Gong E and Wintermark M: Am J Neuroradiol, Journal of Innovative Image Processing (JIIP) 2018; 39(10): 1776-1784. 550(7676): 354-9.